Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "vrsta gradiva" (1) AND "polno besedilo" AND "organizacija" (Onkološki inštitut Ljubljana) .

191 - 200 / 3800
Na začetekNa prejšnjo stran16171819202122232425Na naslednjo stranNa konec
191.
Sonographically guided fine-needle aspiration biopsies of adrenal masses in lung cancer patients, eleven-year experience
Igor Kocijančič, 2004, izvirni znanstveni članek

Povzetek: Purpose. The aim of this retrospective study was to define the accuracy and safety of the ultrasonographically (US) guided fine-needle aspiration biopsy (FNAB) of the enlarged adrenals in the patients with lung cancer. Patients andmethods. In eleven-year period 64 patients with cytologically proven lung cancer underwent USguided FNABs of adrenal masses. The accuracy of the method was assessed on the basis of cytology findings and the safety on the number ofcomplications reported after the procedure. Results. US-guided aspiration biopsy turned out to be accurate in 58/64 cases (91%), and very safe with only4/64 (6%) minor complications. In 52/58 (90%) cases, the cytology sample was found to be malignant. In 6 cases (10%), isolated adrenal masses were adenomas. Conclnsions. We recommend US guided FNAB as a safe and reliable diagnostic method that has many advantages over computer tomography (CT) guided FNAB, such as safety, patient friendliness, no X-rays and its reproducibility.
Objavljeno v DiRROS: 13.02.2024; Ogledov: 103; Prenosov: 25
.pdf Celotno besedilo (93,55 KB)

192.
Choroid plexus carcinoma : a case report
Primož Strojan, Mara Popović, Katarina Šurlan Popović, Berta Jereb, 2004, kratki znanstveni prispevek

Objavljeno v DiRROS: 13.02.2024; Ogledov: 109; Prenosov: 23
.pdf Celotno besedilo (179,15 KB)

193.
Cathepsins and their inhibitors as tumor markers in head and neck cancer
Primož Strojan, 2004, pregledni znanstveni članek

Povzetek: The invasion and metastasizing of tumor cells is closely connected with the disintegration of basement membranes and extracellular matrix. The carriers ofthese processes are different proteolytic enzymes, among them cysteine and aspartic cathepsins B, H, L and D as well, a group of ubiquitous lysosomal proteases, and endogenous inhibitors of the former, cystatins. The aim of the present review was to collect the current knowledge on the predictive and prognostic value of cathepsins and their inhibitors in squamous cell carcinomaof the head and neck. In this particular tumor type, the UICC/AJCC TNM-classification system and histopathological characteristics of the tumors were found inadequate to reliably predict either the response to therapy or patients' survival. Moreover, to date, no factor within the wide spectrum of biochemical and histological factors has yet been idenrified as reliably predicting the natural course of the disease or its response to therapy. To construct a prognostically meaningful tumor profile, new markers are intensively investigated.
Objavljeno v DiRROS: 13.02.2024; Ogledov: 117; Prenosov: 22
.pdf Celotno besedilo (99,21 KB)

194.
Clinical utility of serine proteases in breast cancer
Tanja Čufer, 2004, strokovni članek

Povzetek: The serine protease uPA and its inhibitor PAI-1 are involved in the degradation of tumor stroma and basement membrane. The independent prognostic value of serine protease urokinase-type plasminogen activator uPA and its inhibitor PAI-1 in breast cancer has been almost uniformly confirmed in numerous individual studies as well as in a meta-analysis, including 18 data sets of more than 8,000 patients. According to these observations, the risk ofrelapse in node negative patients with low levels of uPA and PAI-1 is less then 10%; these patients could be spared from toxic adjuvant systemic therapy.Clinically relevant and even more important is the information that uPA and its inhibitor PAI-1 may also have a predictive value for response to either hormonal or cytotoxic therapy in early breast cancer. According to our data obtained from altogether 460 operable breast cancer patients, uPA and PAI-1 may have a predictive value for the response to hormone therapy, but notto chemotherapy. The high PAI-1 levels were associated with a higher risk of relapse in the patients without adjuvant systemic therapy (HR 2.14; C.I. 95%= 0.48-9.56; p=0.321) and in the patients treated with chemotherapy (RR 2.48; C.1. 95%=1.35-4.57; p=0.003). However, in the patients treated with adjuvant hormone therapy, either alone or in combination with chemotherapy, the prognosric value of uPA and PAI-1 was diminished. Moreover, high levels ofboth uPA and PAI-1 were associated with a lower risk of relapse (HR 0.79; p=0.693 and HR 0.26 p= 0.204, respectively). On the basis of currently available evidence, serine protease uPA and its inhibitor PAI-1 are certainly the markers that improve a proper selection of candidates for adjuvant systemic therapy and may also be the markers that could facilitate treatment decision in each individual patient, which is of utmost importance.
Objavljeno v DiRROS: 13.02.2024; Ogledov: 114; Prenosov: 26
.pdf Celotno besedilo (108,14 KB)

195.
Tumor markers in clinical oncology
Srdjan Novaković, 2004, pregledni znanstveni članek

Povzetek: The subtle differences between normal and tumor cells are exploited in the detection and treatment of cancer. These differences are designated as tumor markers and can be either qualitative or quantitative in their nature. That means that both the structures that are produced by tumor cells as well as thestructures that are produced in excessive amounts by host tissues under theinfluence of tumor cells can function as tumor markers. Speaking in general, the tumor markers are the specific molecules appearing in the blood or tissues and the occurrence of which is associated with cancer. According totheir application, tumor markers can be roughly divided as markers in clinical oncology and markers in pathology. In this review, only tumor markersin clinical oncology are going to be discussed. Current tumor markers in clinical oncology include (i) oncofetal antigens, (ii) placental proteins, (iii) hormones, (iv) enzymes, (v) tumor-associated antigens, (vi) special serum proteins, (vii) catecholamine metabolites, and (viii) miscellaneous markers. As to the literature, an ideal tumor marker should fulfil certain criteria - when using it as a test for detection of cancer disease: (1) posirive results should occur in the early stages of the disease, (2) positiveresults should occur only in the patients with a specific type of malignancy, (3) positive results should occur in all patients with the same malignancy, (4) the measured values should correlate with the stage of the disease, (5) the measured values should correlate to the response to treatment, (6) the marker should be easy to measure. Most tumor markers available today meet several, but not all criteria. As a consequence of that, some criteria were chosen for the validation and proper selection of the most appropriate marker in a particular malignancy, and these are: (1) markers' sensitivity, (2) specificity, and (3) predictive values. (Abstract truncated at 2000 characters).
Objavljeno v DiRROS: 13.02.2024; Ogledov: 84; Prenosov: 17
.pdf Celotno besedilo (117,07 KB)

196.
Evaluation of water equivalency of Plastic waterTM for high-energy electron beams using IAEA TRS-398 code of practice
Božidar Casar, Urban Zdešar, Vlado Robar, 2004, izvirni znanstveni članek

Povzetek: Electrochemotherapy (ECT) is a novel method for efficient tumor treatment in clinical environment. It combines local drug delivery and application of shorthigh voltage pulses, which permeabilize the plasma membrane by electroporation. Drug can enter only the cells with permeabilzed membrane. Recently, medical device CliniporatorTM for controlled electroporation was developed. Here, we present a web-application that extends the functionality of this medical device. The aim of the application is to collect, store and toallow the analysis of every ECT application using this medical device. The application helps transferring data collected by dev;ce during the electroporation process to the central database, and enables filling of medical records through the web forms. The application is based on technologies ASP, HTML, Flash, JavaScript, XML and others. The application main advantages are easy and rapid data access, scalability and independence of client computer operating system as well as easy application debugging and upgrading.
Objavljeno v DiRROS: 13.02.2024; Ogledov: 98; Prenosov: 21
.pdf Celotno besedilo (146,09 KB)

197.
Psychosocial coping strategies in cancer patients
Lilijana Šprah, Mojca Šoštarič, 2004, pregledni znanstveni članek

Povzetek: Background. The aim of this review is to present common psychosocial problems in cancer patients and their possible coping strategies. Cancer patients are occupied with many psychosocial problems, which are only partially related to their health state and medical treatments. They are faced with a high social pressure, based on prejudices and stereotypes of this illness. The review presents the process of confrontation with the cancer diagnosis and of managing the psychological consequences of cancer. The effects of specific coping styles, psychosocial interventions and a social support on initiation, progression and recurrence of cancer are also described. Conclusions. Althoughsome recent meta-analysis could not provide scientific evidence for the association befween coping strategies and the cancer initiation, the progression or the recurrence (neither have studies rejected the thesis of association), the therapeutic window for the psychosocial intervention is still wide and shows an important effect on the quality of lives of many cancer patients.
Objavljeno v DiRROS: 07.02.2024; Ogledov: 141; Prenosov: 28
.pdf Celotno besedilo (83,57 KB)

198.
Rituximab affects the prognosis of patients with nonHodgkin's lymphomas
Barbara Jezeršek Novaković, Marjeta Vovk, Simona Borštnar, Radka Tomšič, 2004, izvirni znanstveni članek

Povzetek: Backround. Rituximab - the most widely used monoclonal antibody in the B cell lymphoid malignancies has been applied successfully in the treatment of relapsed and refractory indolent CD20 positive B cell lymphomas and more recently, also in the treatment of aggressive lymphomas in combination with standard chemotherapy. Albeit the chemo-immunotherapy has a wide range of potential applications, there are still several issues that have to be resolved: (1) the optimal scheduling of antibody-chemotherapy combinations, (2) the most active of these combinations, as well as (3) the predictors of response to rituximab. Patients and methods. To facilitate addressing the first two questions, we performed an analysis in 25 patients with different histological types of CD20 positive nonHodgkin's lymphomas (10 aggressive and 15 indolent). Seventeen patients were treated with chemo-immunotherapy for a relapse, and just in 8 patients rituximab was added to first line chemotherapy. Most of the responders received the CHOP regimen, but also otherregimens (FC, BVCPP) were effective in combination with rituximab. Results. The overall response rate was 76%, with 68% complete remissions. The median response duration has not been reached yet. The response was markedly better in the group of previously untreated patients, where the overall response rate reached 100%, with 7 patients in complete and 1 patient in partial remission. Most of the treatment failures occurred in heavily pretreated patients with aggressive lymphomas. No serious adverse effects wereobserved. Conclusion The chemo-immunotherapy improves the treatment outcomes in patients with untreated and relapsed CD20 positive nonHodgkin's lymphomas in comparison to chemotherapy alone. The combined treatment is the most effective when used as soon as possible (preferably as the first line treatment). (Abstract truncated at 2000 characters).
Objavljeno v DiRROS: 07.02.2024; Ogledov: 147; Prenosov: 33
.pdf Celotno besedilo (4,61 MB)

199.
A web-application that extends functionality of medical device for tumor treatment by means of electrochemotherapy
Ivan Pavlović, Peter Kramar, Selma Čorović, David Cukjati, Damijan Miklavčič, 2004, izvirni znanstveni članek

Povzetek: Electrochemotherapy (ECT) is a novel method for efficient tumor treatment in clinical environment. It combines local drug delivery and application of shorthigh voltage pulses, which permeabilize the plasma membrane by electroporation. Drug can enter only the cells with permeabilzed membrane. Recently, medical device CliniporatorTM for controlled electroporation was developed. Here, we present a web-application that extends the functionality of this medical device. The aim of the application is to collect, store and toallow the analysis of every ECT application using this medical device. The application helps transferring data collected by devčce during the electroporation process to the central database, and enables filling of medical records through the web forms. The application is based on technologies ASP, HTML, Flash, JavaScript, XML and others. The application main advantages are easy and rapid data access, scalability and independence of client computer operating system as well as easy application debugging and upgrading.
Ključne besede: neoplasms- drug therapy, drug delivery systems, elektroporation instrumentation
Objavljeno v DiRROS: 07.02.2024; Ogledov: 133; Prenosov: 37
.pdf Celotno besedilo (133,39 KB)

200.
Breast cancer and breast health awareness as an evolving health promotion concept
Andrej Plesničar, Viljem Kovač, Božo Kralj, 2004, izvirni znanstveni članek

Povzetek: Background. Breast cancer is the most frequent malignant disease in the majority of developed countries. In the last few years the introduction of mammography screening programmes has resulted in an improved survival of breast cancer patients. However, the incidence of the disease in these countries is still on the increase. Present focus on secondary breast cancer prevention activities, consisting of early detection and treatment, cannot ensure a decrease of breast cancer incidence. Improved breast health awarenesscould therefore represent a part of specific health promotion activities aimed at decreasing the incidence of breast cancer. Conclusions. Indeveloped countries breast cancer is a significant health care issue. Secondary breast cancer prevention activities should therefore be complementedby specific health promotion activities in order to reduce its incidence in the future. Primary breast cancer prevention would include healthpromotion activities aimed at enhancement of the individual as well as collective breast health awareness. Properly enlightened members of the influential population groups could attain appropriate changes in the fields of legislation, taxation, customs and commercial regulations that would enablewomen to control their own breast health.
Objavljeno v DiRROS: 07.02.2024; Ogledov: 133; Prenosov: 29
.pdf Celotno besedilo (84,20 KB)

Iskanje izvedeno v 0.78 sek.
Na vrh